Comparative Pharmacology
Head-to-head clinical analysis: PULMICORT RESPULES versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMICORT RESPULES versus QVAR 40.
PULMICORT RESPULES vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid